Sponsored Video

Ask the Experts: Meeting the Needs of Patients With Atopic Dermatitis, Plaque Psoriasis, and Seborrheic Dermatitis

Douglas DiRuggiero, DMSc, MHS, PA-C

In this episode of Ask the Experts, dermatology Physician Assistant Douglas DiRuggiero, PA-C, DMSc, shares what's unique about the formulations of ZORYVE® (roflumilast). Mr. DiRuggiero discusses how availability in cream and foam formulations, and approval in both pediatric and adult populations meet the needs of patients with inflammatory skin diseases.

INDICATIONS
ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older.

ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.

ZORYVE topical foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.

ZORYVE topical foam, 0.3%, is indicated for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.

Please see additional IMPORTANT SAFETY INFORMATION below the video.

IMPORTANT SAFETY INFORMATION

ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).

Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.

The most common adverse reactions (≥1%) for ZORYVE cream 0.3% for plaque psoriasis include diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).

The most common adverse reactions (≥1%) for ZORYVE cream 0.15% for atopic dermatitis include headache (2.9%), nausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%).

The most common adverse reactions (≥1%) for ZORYVE foam 0.3% for seborrheic dermatitis include nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).

The most common adverse reactions (≥1%) for ZORYVE foam 0.3% for plaque psoriasis include headache (3.1%), diarrhea (2.5%), nausea (1.7%), and nasopharyngitis (1.3%).

Please see full Prescribing Information for ZORYVE cream and full Prescribing Information for ZORYVE foam.

For more dermatologic disorders content, visit the Disease State Hub. 

Marketed by Arcutis Biotherapeutics, Inc. and Kowa Pharmaceuticals America, Inc.

© 2025 Arcutis Biotherapeutics, Inc. All rights reserved. US-COM-PTF-00653 09/25